Conclusion
Peu d’analyses médico-économiques du dépistage du cancer colorectal dans la population générale ont été entreprises en Europe. La preuve de l’efficacité et de l’intérêt médico-économique du test Hemoccult II® a été apportée par deux études randomisées européennes et une étude contrôlée française. Les tests immunologiques représentent une alternative à ce test, mais les résultats des études cherchant à en démontrer l’efficience sont discordants. Quant au coloscanner et au dépistage génétique, ils n’ont pas encore été évalués en Europe sur le plan médico-économique, faute de données disponibles. La littérature scientifique anglosaxonne est riche d’analyses coût-efficacité du dépistage du cancer colorectal. Mais les hypothèses sur lesquelles reposent les modèles peuvent être discutées. Par ailleurs, les modèles construits diffèrent souvent par les coûts du fait de modes de valorisation sensiblement différents, mais surtout par la nature des hypothèses épidémiologiques utilisées comme l’histoire naturelle de la maladie, les performances diagnostiques des tests et les taux de participation aux campagnes de dépistage.
Ces méthodes pourraient être utilisées uniquement dans des groupes spécifiques à risque de cancer colorectal pour lesquelles il n’existe encore aucune recommandation de dépistage (et notamment chez les parents au premier degré de sujets atteints d’un cancer colorectal après l’âge de 60 ans).
Pour conclure, il apparaît important de développer de nouveaux axes de recherche afin d’apporter des éléments de réponse pertinents et des outils d’aide à la décision sur le plan médico-économique, tant en population générale que dans les groupes à risque élevé de cancer colorectal.
Remerciements à C. Berchi
Preview
Unable to display preview. Download preview PDF.
Références
Moatti JP (1994) Évaluation économique: un complément nécessaire de l’évaluation médicale. In: L’évaluation médicale: du concept à la pratique. Flammarion, Paris, 71–4
Castiel D (2004) Pourquoi une évaluation économique en santé ? In: Le calcul économique en santé. Méthodes et analyses critiques. ENSP, Rennes, 24–8
Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997) Analyse critique de l’évaluation économique. In: Méthodes d’Évaluation Économique des Programmes de Santé. Economica, Paris, 33–57
Auray JP, Bail JN, Béraud C et al. (1998) Recommandation des bonnes pratiques des méthodes d’évaluation économique des stratégies thérapeutiques. Journal d’Economie Médicale 16: 329–51
Siebert U (2003) When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 4: 143–50
Detsky AS, Naglie G, Krahn MD et al. (1997) Primer on medical decision analysis: Part 2—Building a tree. Med Decis Making 17: 126–35
Naimark D, Krahn MD, Naglie G et al. (1997) Primer on medical decision analysis: Part 5—Working with Markov processes. Med Decis Making 17: 152–9
Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13: 437–52
Advisory Committee on Cancer Prevention (2000) Recommendations on cancer screening in the European Union. Eur J Cancer 36: 1473–8
European code against cancer (2005) http://www.cancercode.org/code_11.htm
Gyrd-Hansen D, Sogaard J, Kronborg O (1998) Colorectal cancer screening: efficiency and effectiveness. Health Econ 7: 9–20
Lejeune C, Arveux P, Dancourt V et al. (2004) Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care 20: 434–9
Salked G, Young G, Irwig L et al. (1996) Cost-effectiveness analysis of screening by fæcal occult blood testing for colorectal cancer in Australia. N Z J Public Health 20: 138–43
Whynes DK, Neilson AR, Walker AR, Hardcastle JD (1998) Fæcal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 7: 21–9
Faivre J, Dancourt V, Lejeune C et al. (2004) Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126: 1674–80
Hardcastle JD, Chamberlain JO, Robinson MH et al. (1996) Randomised controlled trial of fæcal-occult-blood screening for colorectal cancer. Lancet 348: 1472–7
Kronborg O, Fenger C, Olsen J et al. (1996) Randomised study of screening for colorectal cancer with fæcal-occult-blood test. Lancet 348: 1467–71
Mandel JS, Bond JH, Church TR et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–71.
Berchi C, Bouvier V, Réaud JM et al. (2003) Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ
Gyrd-Hansen D (1998) Fecal occult blood tests. A cost-effectiveness analysis. Int J Technol Assess Health Care 14: 290–301
Shimbo T, Glick HA, Eisenberg JM (1994) Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care 10: 359–75
Nakama H, Zhang B, Fattah AS (2000) A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer 36: 647–50
Tsuji I, Fukao A, Shoji T et al. (1991) Cost-effectiveness analysis of screening for colorectal cancer in Japan. Tohoku J Exp Med 164: 269–78
Yamamoto M, Nakama H (2000) Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods. Hepatogastroenterology 47: 396–9
Federici A, Giorgi Rossi P, Borgia P et al. (2005) The immunochemical fæcal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 12: 83–8
Frazier AL, Colditz GA, Fuchs CS et al. (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284: 1954–61
Khandker RK, Dulski JD, Kilpatrick JB et al. (2000) A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 16: 799–810
Loeve F, Brown ML, Boer R et al. (2000) Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92: 557–63
Sonnenberg A, Delco F (2002) Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. Arch Intern Med 162: 163–8
Sonnenberg A, Delco F, Inadomi JM (2000) Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer. Ann Intern Med 133: 573–84
Vijan S, Hwang EW, Hofer TP, Hayward RA (2001) Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 111: 593–601
Wagner JL, Tunis S, Brow M (1996) Cost-effectiveness of colorectal cancer screening in average risk adults. In: Prevention and early detection of colorectal cancer. Young GP, Rozen P, and Levin B, London, 321–41
US Preventive Services Task Force (2002) Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 137: 129–31
Pignone M, Saha S, Hoerger T, Mandelblatt J (2002) Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 137: 96–104
UK flexible sigmoidoscopy screening trial investigator (2002) Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 359: 1291–300
Segnan N, Senore C, Andreoni B et al. (2002) Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy”-SCORE. J Natl Cancer Inst 94: 1763–72
Colombo L, Corti G, Magri F et al. (1997) Results of a pilot study of endoscopic screening of first degree relatives of colorectal cancer patients in Italy. J Epidemiol Community Health 51: 453–8
Pariente A, Milan C, Lafon J, Faivre J (1998) Colonoscopic screening in first-degree relatives of patients with’ sporadic’ colorectal cancer: a case-control study. Gastroenterology 115: 7–12
Barish MA (2005) The Economics of Virtual Colonoscopy http://www.imagingeconomics.com/library/200112-09.asp
Smith CS, Fenlon HM (2002) Virtual colonoscopy. In: Clinical gastroenterology. Cancer of the colon and rectum. Tytgat GNJ, London, 219–36
Sonnenberg A, Delco F, Bauerfeind P (1999) Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Am J Gastroenterol 94: 2268–74
Heitman SJ, Manns BJ, Hilsden RJ, Fong A et al. (2005) Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening. Cmaj 173: 877–81
Leshno M, Halpern Z, Arber N (2003) Cost-effectiveness of colorectal cancer screening in the average risk population. Health Care Manag Sci 6: 165–74
Song K, Fendrick AM, Ladabaum U (2004) Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126: 1270–9
Conférence de consensus (1998) Prévention, dépistage et prise en charge des cancers du colon. Gastroenterol Clin Biol 22: S275–88
Eisinger F, Giordanella JP, Didelot R et al. (1996) Pratiques de dépistage et antécédents familiaux de cancer colorectal. Gastroenterol Clin Biol 20: 627–32
Luchtefeld MA, Syverson D, Solfelt M et al. (1991) Is colonoscopic screening appropriate in asymptomatic patients with family history of colon cancer? Dis Colon Rectum 34: 763–8
Eddy DM, Nugent FW, Eddy JF et al. (1987) Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology 92: 682–92
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Lejeune, C. (2006). Approche médico-économique du dépistage du cancer colorectal. In: Le dépistage du cancer colorectal. Dépistage et cancer. Springer, Paris. https://doi.org/10.1007/2-287-32803-3_7
Download citation
DOI: https://doi.org/10.1007/2-287-32803-3_7
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-32802-2
Online ISBN: 978-2-287-32803-9